WuXi PharmaTech and British-based AstraZeneca Hold Media Round Table

WuXi PharmaTech and British-based AstraZeneca Hold Media Round Table

September 07, 2006

 

    SHANGHAI, China, Sept. 7 /Xinhua-PRNewswire/ -- WuXi
PharmaTech, China's leading pharmaceutical R&D service
company, and AstraZeneca, one of the world's largest
pharmaceutical companies, jointly held a media round table
on Aug. 25 at WuXi PharmaTech's Shanghai headquarters to
celebrate their two-year, US$ 14 million collaboration.

    (Logo:
http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

    At the Media Round Table, AstraZeneca promoted its
position of "in China for China."  When asked if
the collaborative relationship between the two companies
would be expanded, James Cai, vice president of R&D for
AstraZeneca China elaborated that, "Thus far the
relationship has been very successful, should this
continue, I see no reason that our efforts and
collaboration will not expand."

    AstraZeneca has cooperated with WuXi PharmaTech as a
local collaborative partner to, "not only take
advantage of the relatively lower cost of operation, but
also focus on the differences between diseases of China and
those of the west," said James Cai.

    Dr. Ge Li, Chairman and CEO of WuXi PharmaTech
expressed great faith in this collaboration by adding,
"This is a win-win opportunity for both sides. For
WuXi PharmaTech, this is a great opportunity to learn the
most advanced R&D techniques and to improve our
operation and customer services.  This kind of partnership
will certainly help us to become a first-class R&D
service company. " 

    AstraZeneca seeks to utilize its WuXi PharmaTech
collaboration and in-China research centers to discover and
develop drugs specific to Chinese market, which is
forecasted to grow to fifth largest pharmaceutical market
in the world by 2010.

    For more information, please contact:

     Sherry Shao 
     Tel:   [phone]
     Email: [e-mail]

SOURCE  WuXi PharmaTech Co., Ltd.